Skip to main content
. 2023 Apr 13;14:2102. doi: 10.1038/s41467-023-37179-4

Fig. 3. Quantitative histopathology imaging predicts stage I and II colorectal cancer patients’ progression-free survival outcomes.

Fig. 3

A MOMA-trained models differentiate patients with early relapse or death from those with longer progression-free survival using histopathology images (two-sided log-rank test P-value=0.02). B We successfully validate our models using the independent external validation set from the Nurses’ Health Study and Health Professionals Follow-up Study cohorts (two-sided log-rank test P-value<0.005). C Interpretation of the progression-free survival prediction model. The prediction of a patient with longer-term survival is shown in this figure panel. Mucosal regions and regions occupied by cancer cells both receive high attention weights in the overall survival prediction task. D Model prediction of a patient with shorter-term overall survival. In samples collected from shorter-term survivors, our model also focuses on regions of lymphocytes when making predictions. MUC: mucus; TUM: colorectal adenocarcinoma epithelium; STR: cancer-associated stroma; LYM: lymphocytes.